MyFinsight
Home
Blog
About
Proceeds from issuance of
term debt, net of...
$25,000K
(150.00%↑ Y/Y)
Proceeds from issuance of
common stock under atm,...
$2,373K
Proceeds from exercise of
stock options
$508K
Net cash provided by
financing activities
$27,881K
(179.20%↑ Y/Y)
Net change in cash,
cash equivalents and...
$19,198K
(479.93%↑ Y/Y)
Canceled cashflow
$8,683K
Net loss
$74,141K
(424.81%↑ Y/Y)
Non-cash interest
expense
$6,628K
(-10.41%↓ Y/Y)
Stock-based compensation
expense
$3,391K
(150.07%↑ Y/Y)
Depreciation expense
$591K
Change in right-of-use
asset
-$511K
(56.80%↑ Y/Y)
Accounts payable and
accrued liabilities
$206K
(125.18%↑ Y/Y)
Net cash used in
operating activities
-$8,666K
(41.41%↑ Y/Y)
Net cash used in
investing activities
-$17K
(93.15%↑ Y/Y)
Canceled cashflow
$85,468K
Change in fair value of
the convertible...
-$91,018K
(-16709.12%↓ Y/Y)
Purchases of property and
equipment
$17K
(-93.15%↓ Y/Y)
Prepaid expenses and
other assets
$2,013K
(71.61%↑ Y/Y)
Accrued compensation
-$772K
(-10.92%↓ Y/Y)
Operating lease liability
-$331K
(34.58%↑ Y/Y)
Back
Back
Cash Flow
Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP)
source: myfinsight.com